Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × entrectinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4 Neoplasm Metastasis 2 Melanoma 2 Breast Neoplasms 2 Brain Neoplasms 2 Thyroid Cancer, Papillary 1 Solid Tumors 1 Sarcoma 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Noonan Syndrome 6 1 Neuroendocrine Tumors 1 Lymphoma, Large-Cell, Anaplastic 1 Locally Advanced Thyroid Gland Carcinoma 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Lobular 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡